登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Science，4月24日，Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-04-25

  • Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

    Linlin Zhang1,2, Daizong Lin1,3, Xinyuanyuan Sun1,2, Ute Curth4, Christian Drosten5, Lucie Sauerhering6,7, Stephan Becker6,7, Katharina Rox8,9, Rolf Hilgenfeld1,2,*

    See all authors and affiliations

    Science 24 Apr 2020:

    Vol. 368, Issue 6489, pp. 409-412

    DOI: 10.1126/science.abb3405

    Abstract

    The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2) is a global health emergency. An attractive drug target among coronaviruses is the main protease (Mpro, also called 3CLpro) because of its essential role in processing the polyproteins that are translated from the viral RNA. We report the x-ray structures of the unliganded SARS-CoV-2 Mpro and its complex with an α-ketoamide inhibitor. This was derived from a previously designed inhibitor but with the P3-P2 amide bond incorporated into a pyridone ring to enhance the half-life of the compound in plasma. On the basis of the unliganded structure, we developed the lead compound into a potent inhibitor of the SARS-CoV-2 Mpro. The pharmacokinetic characterization of the optimized inhibitor reveals a pronounced lung tropism and suitability for administration by the inhalative route.

  • 原文来源：https://science.sciencemag.org/content/368/6489/409
118浏览量
原文链接
相关报告

  • 《Science，4月22日，Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-04-23
    • Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease Wenhao Dai1,2,*, Bing Zhang4,*, Haixia Su1,*, Jian Li1,5, Yao Zhao3, Xiong Xie1, Zhenming Jin1, Fengjiang Liu3, Chunpu Li1, You Li6, Fang Bai3, Haofeng Wang3, Xi Cheng1, Xiaobo Cen6, Shulei Hu1, Xiuna Yang3, Jiang Wang1, Xiang Liu7, Gengfu Xiao4, Hualiang Jiang1,2,3, Zihe Rao3, Lei-Ke Zhang4,†, Yechun Xu1,†, Haitao Yang3,†, Hong Liu1,2,5,† See all authors and affiliations Science 22 Apr 2020: eabb4489 DOI: 10.1126/science.abb4489 Abstract SARS-CoV-2 is the etiological agent responsible for the global COVID-19 outbreak. The main protease (Mpro) of SARS-CoV-2 is a key enzyme that plays a pivotal role in mediating viral replication and transcription. We designed and synthesized two lead compounds (11a and 11b) targeting Mpro. Both exhibited excellent inhibitory activity and potent anti-SARS-CoV-2 infection activity. The X-ray crystal structures of SARS-CoV-2 Mpro in complex with 11a or 11b, both determined at 1.5 Å resolution, showed that the aldehyde groups of 11a and 11b are covalently bound to Cys145 of Mpro. Both compounds showed good PK properties in vivo, and 11a also exhibited low toxicity, suggesting that these compounds are promising drug candidates.
    57浏览量
    原文链接

  • 《Nature，9月4日，Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-09-15
    • Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease Lifeng Fu, Fei Ye, Yong Feng, Feng Yu, Qisheng Wang, Yan Wu, Cheng Zhao, Huan Sun, Baoying Huang, Peihua Niu, Hao Song, Yi Shi, Xuebing Li, Wenjie Tan, Jianxun Qi & George Fu Gao Nature Communications volume 11, Article number: 4417 (2020) Abstract COVID-19 was declared a pandemic on March 11 by WHO, due to its great threat to global public health. The coronavirus main protease (Mpro, also called 3CLpro) is essential for processing and maturation of the viral polyprotein, therefore recognized as an attractive drug target. Here we show that a clinically approved anti-HCV drug, Boceprevir, and a pre-clinical inhibitor against feline infectious peritonitis (corona) virus (FIPV), GC376, both efficaciously inhibit SARS-CoV-2 in Vero cells by targeting Mpro. Moreover, combined application of GC376 with Remdesivir, a nucleotide analogue that inhibits viral RNA dependent RNA polymerase (RdRp), results in sterilizing additive effect. Further structural analysis reveals binding of both inhibitors to the catalytically active side of SARS-CoV-2 protease Mpro as main mechanism of inhibition. Our findings may provide critical information for the optimization and design of more potent inhibitors against the emerging SARS-CoV-2 virus.
    136浏览量
    原文链接